The investigational product, TVGN 920, will be manufactured utilizing Tevogen’s proprietary ExacTcell™ technology, in which genetically unmodified, allogeneic cytotoxic CD8+ CTLs with precise targets across the HPV genome, will be tested in safety and feasibility studies. Tevogen aims to evaluate the potential of TVGN 920 in treating HPV, a known trigger of cervical cancer, which often persists in women following treatment for high-grade cervical lesions. The goal is to prevent recurrent lesions that could eventually lead to cervical cancer and eradicate HPV infection to prevent transmission of the virus.
“Ability to eradicate HPV in women should offer the dual benefit of preventing recurrent cervical pathology and potentially cervical cancer, as well as interrupting the cycle of HPV transmission, a critical public health concern,” said Dr. Dolores Grosso, DNP, the Clinical Development Lead at Tevogen.
“Several cancers are triggered by viral infections. We hope that success in our efforts will open the door to new treatments for other virus-associated cancers,” commented Dr. Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer.
“Tevogen’s goal is to provide access to the vast and unprecedented potential of personalized immunotherapies for large patient populations impacted by common cancers and viral infections. This is reflected by Tevogen’s research pipeline which includes treatment for HPV and other serious viral infections and cancers using our precision T cell platform,” said Tevogen founder and CEO Dr. Ryan Saadi, MD, MPH, 2023 Nobel Peace Prize nominee.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!